| Patent Number |
Title Of Patent |
Date Issued |
| RE39192 |
Supplemented and unsupplemented tissue sealants, methods of their production and use |
July 18, 2006 |
| This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or |
| 7435869 |
Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin |
October 14, 2008 |
| A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals |
| 7393628 |
Method for enriching adherent monocyte populations |
July 1, 2008 |
| The present invention provides methods and apparatus for the rapid and efficient collection and purification of activated monocytes. The methods and apparatus of the present invention provide means for effecting the collection and purification in an aseptic environment. The method in |
| 7365173 |
Method for the production of pure virally inactivated butyrylcholinesterase |
April 29, 2008 |
| The present invention provides a method for purifying butyrylcholinesterase from various biological fluids. Biological fluids include, e.g., blood, blood fractions, plasma, and bioreactor broths, and other such mixtures containing butyrylcholinesterase. In one embodiment, the inventi |
| 7264953 |
Mutant proteinase-inhibitors and uses thereof |
September 4, 2007 |
| A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinas |
| 6846636 |
Methods and compositions for HDL holoparticle uptake receptor |
January 25, 2005 |
| The present invention provides an isolated mammalian receptor which specifically binds a high density lipoprotein holoparticle, comprising a subunit of approximately 45-600 kDa molecular weight and one or more subunits selected from the group consisting of a subunit of approximately |
| 6518482 |
Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor |
February 11, 2003 |
| A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal p |
| 6489143 |
Mutant plasminogen activator-inhibitor type 1 (PAI-1) proteins |
December 3, 2002 |
| Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at posi |
| 6447775 |
Modulators of expression and function of LRP in Alzheimer's disease |
September 10, 2002 |
| The present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid .beta.-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members o |
| 6436344 |
Method of inactivating pathogens |
August 20, 2002 |
| The present invention introduces a class of compounds, 2-substituted carbonyl compounds, that are useful as disinfecting agents, and particularly useful in methods for the disinfection of biological fluids. Members of the class of compounds have been found to possess pathogen inactiv |
| 6255554 |
Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor |
July 3, 2001 |
| A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal p |
| 6245548 |
Activation of pure prothrombin to thrombin with about 30% to about 40% sodium citrate |
June 12, 2001 |
| A method for the production of thrombin from pure prothrombin is provided by converting pure prothrombin by treating pure prothrombin with sodium citrate in the absence of additional coagulation factors. Preferrably, a solution is used containing about 30% to about 40% sodium citrate. |
| 6193891 |
Methods for the selective separation of organic components from biological fluids |
February 27, 2001 |
| The present invention pertains to improved methods for the selective separation of organic components from biological fluids. More particularly, the present invention pertains to methods for the selective separation of organic components from biological fluids which comprise the step |
| 6106773 |
Pathogen inactivating compositions for disinfecting biological fluids |
August 22, 2000 |
| The present invention is directed to pathogen inactivating compositions that can be used to disinfect various biological fluids, such as blood, blood fractions, and the like. The compositions are suitable for disinfecting biological fluids containing valuable, but labile, components |
| 6103498 |
Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof |
August 15, 2000 |
| Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at pos |
| 6096216 |
Iodinated matrices for disinfecting biological fluids |
August 1, 2000 |
| The present invention provides media for inactivating pathogens found within protein-containing biological fluids. The media of the present invention preserve the structural integrity and biological activity of labile proteins while simultaneously exhibiting potent disinfectant activ |
| 6093804 |
Method for purification of alpha-1 proteinase inhibitor |
July 25, 2000 |
| The methods of the present invention provide a simple means for separating active and inactive Alpha Proteinase Inhibitor (API). The methods further provide means for purifying API at high yield (>70%), and at levels of purity (>90%) and activity (>90%) not heretofore available. |
| 5922598 |
Reducing tissue immunogenicity by induction of apoptosis |
July 13, 1999 |
| A cell is subjected to apoptosis, a genetically programmed autolysis of the cell. Cells of a specific type, classified by function, maturity, source, etc. can be effectively removed from a mixture of cells in a tissue or cell suspension by their different sensitivities to the pressure-ti |
| 5880327 |
Transgenic mammals expressing human coagulation factor VIII |
March 9, 1999 |
| A non-human transgenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal p |
| 5487971 |
Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
January 30, 1996 |
| The invention is a sterile, plasma-free storage medium for blood components including red blood cells and for platelets processed separately or together. The red cell storage medium includes adenine and a physiologically compatible, aqueous electrolyte solution. In one liter of this |
| 5403596 |
Factor Xa inhibitor and pharmaceutical compositions containing same |
April 4, 1995 |
| A novel anticoagulant/modulator factor isolated from the saliva of the meinal leech Hirudo medicinalis, specifically inhibiting bovine Xa factor but not inhibiting bovine thrombin. |
| 5330439 |
Safety device for use in collecting fluid samples |
July 19, 1994 |
| A safety device for collecting fluids for laboratory testing is disclosed. More particularly, the invention relates to an apparatus for collecting multiple undiluted blood samples for subsequent laboratory testing wherein the apparatus is provided with a safety overshield which precludes |
| 5248506 |
Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
September 28, 1993 |
| The invention is a sterile, plasma-free storage medium for blood components including red blood cells and for platelets processed separately or together. The red cell storage medium includes a physiologically compatible, aqueous electrolyte solution. In one liter of this electrolyte |
| 4911703 |
Mobile, self-contained blood collection system and method |
March 27, 1990 |
| Methods and systems for collection of blood components, such as plasma, from donors are provided. One method includes the steps of collecting a unit of whole blood froma donor; forcing the collected blood unit through a plasma separator; accumulating the plasma in a container; and return |
| 4908314 |
Protein C activator |
March 13, 1990 |
| A protein C activator is purified from the venom of the Southern copperhead snake. The resultant enzyme is a very specific and efficient activator of protein C. The high efficiency and specificity enables the sensitive measurement of functional protein C levels in plasma and other biolog |
| 4622302 |
Process for inducing membrane fusion under an electric field |
November 11, 1986 |
| A device and process for inducing membrane fusion under an electric field. The process comprises the steps of (a) suspending said membranes in an aqueous buffered medium in a manner so that the membranes are without contact with each other; (b) altering said membranes to a fusogenic stat |
| 4608255 |
Biocompatible method for in situ production of functional platelets and product produced thereby |
August 26, 1986 |
| The present invention discloses the effect of ultraviolet (UV) radiation on platelet concentrates collected in a plastics container, particularly in a polypropylene bag. Samples irradiated at 310 nm for 30 minutes at a dose of 774 J/M.sup.2 show no loss of platelet function as determined |
| 4585735 |
Prolonged storage of red blood cells |
April 29, 1986 |
| The present invention discloses a hypotonic suspension medium and a method for prolonged storage of red blood cells at about 4.degree. C. The suspension medium comprises about 80-150 mM glucose, 30-80 mM mannitol, 6-90 mM potassium citrate, 1-5 mM adenine and 10-200 mM ammonium chloride |
| 4559298 |
Cryopreservation of biological materials in a non-frozen or vitreous state |
December 17, 1985 |
| A method is provided for the successful cryopreservation of biological materials including whole organs, organ sections, tissues and cells, in a non-frozen (vitreous) state, comprising cooling the biological material to be preserved under pressure in the presence of a non-toxic vitrifabl |
| 4557717 |
Cup insert for balancing |
December 10, 1985 |
| A centrifuge cup insert having an outer container and an inner container disposed therein with a spacer means between the containers to afford a reservoir between the containers capable of holding a liquid, the reservoir communicating with the atmosphere; associated apparatus for wei |
| 4447416 |
Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement the |
May 8, 1984 |
| Plasma concentrates of vitamin-K dependent clotting factors of reduced thrombogenic potential useful for clinical replacement therapy in deficiency diseases of these clotting factors are provided. Preferably, concentrates substantially devoid of zymogens extraneous to the deficient f |
| 4420398 |
Filteration method for cell produced antiviral substances |
December 13, 1983 |
| This invention affords a filtration method and apparatus for extracting cell produced antiviral substances (CPAS) from a production broth using cross-flow membrane filtration. The broth is perfused into a first filtration cell and caused to cross-flow across an ultrafiltration membra |
| 4379085 |
Heat stabilization of plasma proteins |
April 5, 1983 |
| A method for the heat stabilization of a plasma protein such as C1-INA or Factor IX comprising heating the protein in an aqueous medium in the presence of potassium or ammonium citrate in an amount of from in excess of 2.0 M to saturation of the medium. The method is particularly app |
| 4264449 |
Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification th |
April 28, 1981 |
| An antibody-specific solid phase immunoadsorbent is prepared by adsorptively binding a lipid-containing viral antigen, such as hepatitis B surface antigen, to the surface of a porous glass carrier having an average pore diameter within the range of about 40-200 nm and an adsorptive s |
| 4255788 |
Phasing detector for continuous flow systems |
March 10, 1981 |
| A phasing system is provided for parallel channel continuous flow systems wherein the individual test channels have different flow times although intersample timing is constant. A phasing sample is introduced and its presence is sensed at the output of each of the parallel test channels. |
| 4232004 |
Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification th |
November 4, 1980 |
| An antibody-specific solid phase immunoadsorbent is prepared by adsorptively binding a lipid-containing viral antigen, such as hepatitis B surface antigen, to the surface of a porous glass carrier having an average pore diameter within the range of about 40-200 nm and an adsorptive s |
| 4222934 |
Preparation of albumin using ethanol |
September 16, 1980 |
| Methods for the large scale preparation of clinical albumin are disclosed. One method includes dilution of plasma with a NaCl solution containing disodium ethylene dinitrilo tetraacetate and a stabilizer such as sodium caprylate. The resulting solution is then subjected to heating and co |
| 4199954 |
Method of storing physiological material |
April 29, 1980 |
| Human cells or tissue in suspension or immersion in physiological solution are stored at a basic storage temperature of about 4.degree. C., and periodically subjected to a higher temperature within the range of from 25.degree.-37.degree. C. for a period of time and at intervals sufficien |
| 4164496 |
Preparation of albumin using PEG and EDTA |
August 14, 1979 |
| Methods for the large scale preparation of clinical albumin are disclosed. One method includes dilution of plasma with a NaCl solution containing disodium ethylene dinitrilo tetraacetate and a stabilizer such as sodium caprylate. The resulting solution is then subjected to heating and co |
| 4104266 |
Method for preparation of antihemophilic factor |
August 1, 1978 |
| An improved method for preparation of purified AHF is disclosed. The method includes the cryoprecipitation of plasma, followed by a cold extraction of the cryoprecipitate at low temperature, approximately 0.degree. C, to obtain a cold insoluble fraction. The cold insoluble fraction is th |
| 4078783 |
Apparatus for use in a blood collection system |
March 14, 1978 |
| Apparatus for use in a blood collection system comprising a combined armrest/writing/worksurface adapted to be supported for adjustable movement on a donor lounge. An upper elongated generally horizontally extending trough supports the arm of a donor during venipuncture. An inclined |
| 4057288 |
Stackable wheeled chair |
November 8, 1977 |
| A stackable wheeled chair particularly for use in a mobile blood collection system. Each chair comprises a pair of laterally spaced, generally inverted U-shaped leg means. Each leg means includes front and rear leg members which diverge downwardly from an upper connecting member with |
